fluconazole has been researched along with Co-infection in 27 studies
Fluconazole: Triazole antifungal agent that is used to treat oropharyngeal CANDIDIASIS and cryptococcal MENINGITIS in AIDS.
fluconazole : A member of the class of triazoles that is propan-2-ol substituted at position 1 and 3 by 1H-1,2,4-triazol-1-yl groups and at position 2 by a 2,4-difluorophenyl group. It is an antifungal drug used for the treatment of mucosal candidiasis and for systemic infections including systemic candidiasis, coccidioidomycosis, and cryptococcosis.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Cryptococcal antigen screening is recommended among people living with AIDS when entering HIV care with a CD4 count of <100 cells/μl, and preemptive fluconazole monotherapy treatment is recommended for those with subclinical cryptococcal antigenemia." | 5.20 | Increased Antifungal Drug Resistance in Clinical Isolates of Cryptococcus neoformans in Uganda. ( Achan, B; Akampurira, A; Alhadab, AA; Boulware, DR; Hullsiek, KH; McDonald, TR; Meya, DB; Nielsen, K; Okagaki, LH; Rhein, JR; Smith, KD, 2015) |
| " provided a novel perspective by identifying synergism between fluconazole and bacterial antagonism in the context of Candida albicans-Pseudomonas aeruginosa co-infection." | 4.12 | Competition for Iron during Polymicrobial Infections May Increase Antifungal Drug Susceptibility-How Will It Impact Treatment Options? ( Pohl, CH, 2022) |
| " Clinical features and outcome were compared in 25 (41%) Candida-positive patients (6 (22%) fluconazole-resistant Candida glabrata) and 36 patients without Candida infection." | 3.81 | Positive peritoneal fluid fungal cultures in postoperative peritonitis after bariatric surgery. ( Chochillon, C; Desmard, M; Houze, S; Marmuse, JP; Montravers, P; Ribeiro-Parenti, L; Zappella, N, 2015) |
| "The prevalence of fungal secondary infections among COVID-19 patients and efficacy of antifungal therapy used in such patients is still unknown." | 2.82 | Antifungal therapy in the management of fungal secondary infections in COVID-19 patients: A systematic review and meta-analysis. ( Kumar, TMP; Pathakamuri, N; Ramaswamy, S; Ramesh, M; Sah, SK; Shariff, A; Srikanth, MS; Undela, K, 2022) |
| " The objective of this study was to compare the survival benefit between 5-FC (flucytosine) and fluconazole as second-line drugs given in combination with AmB." | 2.50 | Comparison of flucytosine and fluconazole combined with amphotericin B for the treatment of HIV-associated cryptococcal meningitis: a systematic review and meta-analysis. ( Lin, DF; Lu, X; Shen, C; Yao, ZW, 2014) |
| "Polymicrobial infections are challenging to treat because we don't fully understand how pathogens interact during infection and how these interactions affect drug efficacy." | 1.72 | Pseudomonas Synergizes with Fluconazole against ( Dagher, AM; Hattab, S; Wheeler, RT, 2022) |
| " The objective of this study was to find an effective drug combination to treat dual-species cultures of fungi and bacteria." | 1.72 | Synergistic Effects of Fluconazole Combined with Doxycycline Against Dual-Species Cultures of ( Gao, Y; Gong, L; Li, X; Lun, Z; Xu, A; Zhang, Z, 2022) |
| "The present study showed that mixed infections exist and could be of particular importance for care outcomes." | 1.51 | Cryptococcus genetic diversity and mixed infections in Ivorian HIV patients: A follow up study. ( Bellet, V; Bertout, S; Chabrol, A; Delaporte, E; Doumbia, A; Drakulovski, P; Kakou, A; Kassi, FK; Krasteva, D; Landman, R; Menan, HEI; Reynes, J; Roger, F, 2019) |
| "Fluconazole was not effective against preformed mixed- Candida species biofilms while amphotericin B was potent." | 1.48 | Dynamics of Mixed- Candida Species Biofilms in Response to Antifungals. ( Herrera, M; Kadosh, D; Li, X; Mintz, J; Vipulanandan, G; Wickes, BL; Wiederhold, NP, 2018) |
| "There predominant combinations of mixed infection were 14 Candida albicans/Candida glabrata, 13 C." | 1.48 | Mixed yeast infections in Taiwan. ( Chen, PN; Chu, WL; Lin, CC; Lo, HJ; Yang, YL; Zhou, ZL, 2018) |
| "Cryptococcosis is an important opportunistic infection of organ transplant recipients." | 1.48 | Cryptococcoma of a transplanted kidney in a patient presenting with recurrent urinary tract infection: a case report. ( Greeff, L; Karusseit, VOL; Lengano, T; Muranda, AZ; Sathekge, MM, 2018) |
| "Fungal endocarditis was confirmed by culturing of the resected vegetation showing mixed growth of Candida albicans and Candida tropicalis, although three consecutive blood cultures were negative for Candida species." | 1.39 | Endocarditis due to a co-infection of Candida albicans and Candida tropicalis in a drug abuser. ( Abbasi, K; Anvari, MS; Badali, H; Boroumand, M; Fesharaki, SH; Haghani, I; Kargar, ML; Meis, JF; Mousavi, B, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 18 (66.67) | 24.3611 |
| 2020's | 9 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Hattab, S | 1 |
| Dagher, AM | 1 |
| Wheeler, RT | 1 |
| Pohl, CH | 1 |
| Gao, Y | 2 |
| Zhang, Z | 1 |
| Lun, Z | 1 |
| Gong, L | 1 |
| Xu, A | 1 |
| Li, X | 2 |
| Sah, SK | 1 |
| Shariff, A | 1 |
| Pathakamuri, N | 1 |
| Ramaswamy, S | 1 |
| Ramesh, M | 1 |
| Undela, K | 1 |
| Srikanth, MS | 1 |
| Kumar, TMP | 1 |
| Yazdanpanah, S | 2 |
| Ahmadi, M | 2 |
| Zare, Z | 2 |
| Nikoupour, H | 2 |
| Arabsheybani, S | 2 |
| Jabrodini, A | 2 |
| Eghtedarnejad, E | 2 |
| Chamanpara, P | 2 |
| Geramizadeh, B | 2 |
| Anbardar, MH | 2 |
| Malekizadeh, Z | 2 |
| Gashtasebi, M | 2 |
| Mohsenzadeh, M | 2 |
| Shafiekhani, M | 2 |
| Zomorodian, K | 2 |
| Kassi, FK | 1 |
| Drakulovski, P | 1 |
| Bellet, V | 1 |
| Roger, F | 1 |
| Chabrol, A | 1 |
| Krasteva, D | 1 |
| Doumbia, A | 1 |
| Landman, R | 1 |
| Kakou, A | 1 |
| Reynes, J | 1 |
| Delaporte, E | 1 |
| Menan, HEI | 1 |
| Bertout, S | 1 |
| Rujirachun, P | 1 |
| Sangwongwanich, J | 1 |
| Chayakulkeeree, M | 1 |
| Sadamatsu, H | 1 |
| Takahashi, K | 1 |
| Tashiro, H | 1 |
| Ogusu, S | 1 |
| Haraguchi, T | 1 |
| Nakashima, C | 1 |
| Nakamura, T | 1 |
| Sueoka-Aragane, N | 1 |
| Saconi, ES | 1 |
| de Carvalho, VC | 1 |
| de Oliveira, PRD | 1 |
| Lima, ALLM | 1 |
| Xie, O | 1 |
| Streitberg, R | 1 |
| Hughes, C | 1 |
| Stuart, R | 1 |
| Graham, M | 1 |
| Vipulanandan, G | 1 |
| Herrera, M | 1 |
| Wiederhold, NP | 1 |
| Mintz, J | 1 |
| Wickes, BL | 1 |
| Kadosh, D | 1 |
| Yang, YL | 1 |
| Chu, WL | 1 |
| Lin, CC | 1 |
| Zhou, ZL | 1 |
| Chen, PN | 1 |
| Lo, HJ | 1 |
| Ren, X | 1 |
| Liu, W | 2 |
| Liu, Y | 1 |
| Muranda, AZ | 1 |
| Greeff, L | 1 |
| Sathekge, MM | 1 |
| Lengano, T | 1 |
| Karusseit, VOL | 1 |
| Loyse, A | 1 |
| Burry, J | 1 |
| Cohn, J | 1 |
| Ford, N | 1 |
| Chiller, T | 1 |
| Ribeiro, I | 1 |
| Koulla-Shiro, S | 1 |
| Mghamba, J | 1 |
| Ramadhani, A | 1 |
| Nyirenda, R | 1 |
| Aliyu, SH | 1 |
| Wilson, D | 1 |
| Le, T | 1 |
| Oladele, R | 1 |
| Lesikari, S | 1 |
| Muzoora, C | 1 |
| Kalata, N | 1 |
| Temfack, E | 1 |
| Mapoure, Y | 1 |
| Sini, V | 1 |
| Chanda, D | 1 |
| Shimwela, M | 1 |
| Lakhi, S | 1 |
| Ngoma, J | 1 |
| Gondwe-Chunda, L | 1 |
| Perfect, C | 1 |
| Shroufi, A | 1 |
| Andrieux-Meyer, I | 1 |
| Chan, A | 1 |
| Schutz, C | 1 |
| Hosseinipour, M | 1 |
| Van der Horst, C | 1 |
| Klausner, JD | 1 |
| Boulware, DR | 2 |
| Heyderman, R | 1 |
| Lalloo, D | 1 |
| Day, J | 1 |
| Jarvis, JN | 2 |
| Rodrigues, M | 1 |
| Jaffar, S | 1 |
| Denning, D | 1 |
| Migone, C | 1 |
| Doherty, M | 1 |
| Lortholary, O | 1 |
| Dromer, F | 1 |
| Stack, M | 1 |
| Molloy, SF | 2 |
| Bicanic, T | 1 |
| van Oosterhout, J | 1 |
| Mwaba, P | 1 |
| Kanyama, C | 1 |
| Kouanfack, C | 1 |
| Mfinanga, S | 1 |
| Govender, N | 1 |
| Harrison, TS | 2 |
| Tambe, S | 1 |
| Zambare, U | 1 |
| Nayak, C | 1 |
| Ergin, G | 1 |
| Deger, SM | 1 |
| Guz, G | 1 |
| Fesharaki, SH | 1 |
| Haghani, I | 1 |
| Mousavi, B | 1 |
| Kargar, ML | 1 |
| Boroumand, M | 1 |
| Anvari, MS | 1 |
| Abbasi, K | 1 |
| Meis, JF | 1 |
| Badali, H | 1 |
| Yao, ZW | 1 |
| Lu, X | 1 |
| Shen, C | 1 |
| Lin, DF | 1 |
| Kamikawa, Y | 1 |
| Mori, Y | 1 |
| Nagayama, T | 1 |
| Fujisaki, J | 1 |
| Hirabayashi, D | 1 |
| Sakamoto, R | 1 |
| Hamada, T | 1 |
| Sugihara, K | 1 |
| Li, H | 1 |
| Zhang, C | 1 |
| Liu, P | 1 |
| Sun, S | 1 |
| Kong, EF | 1 |
| Kucharíková, S | 1 |
| Van Dijck, P | 1 |
| Peters, BM | 1 |
| Shirtliff, ME | 1 |
| Jabra-Rizk, MA | 1 |
| Zappella, N | 1 |
| Desmard, M | 1 |
| Chochillon, C | 1 |
| Ribeiro-Parenti, L | 1 |
| Houze, S | 1 |
| Marmuse, JP | 1 |
| Montravers, P | 1 |
| Molefi, M | 1 |
| Chofle, AA | 1 |
| Kalluvya, S | 1 |
| Changalucha, JM | 1 |
| Cainelli, F | 1 |
| Leeme, T | 1 |
| Lekwape, N | 1 |
| Goldberg, DW | 1 |
| Haverkamp, M | 1 |
| Bisson, GP | 1 |
| Perfect, JR | 1 |
| Letang, E | 1 |
| Fenner, L | 1 |
| Meintjes, G | 1 |
| Burton, R | 1 |
| Makadzange, T | 1 |
| Ndhlovu, CE | 1 |
| Hope, W | 1 |
| Smith, KD | 1 |
| Achan, B | 1 |
| Hullsiek, KH | 1 |
| McDonald, TR | 1 |
| Okagaki, LH | 1 |
| Alhadab, AA | 1 |
| Akampurira, A | 1 |
| Rhein, JR | 1 |
| Meya, DB | 1 |
| Nielsen, K | 1 |
| Tati, S | 1 |
| Davidow, P | 1 |
| McCall, A | 1 |
| Hwang-Wong, E | 1 |
| Rojas, IG | 1 |
| Cormack, B | 1 |
| Edgerton, M | 1 |
| Ben-Ami, R | 1 |
| Olshtain-Pops, K | 1 |
| Krieger, M | 1 |
| Oren, I | 1 |
| Bishara, J | 1 |
| Dan, M | 1 |
| Wiener-Well, Y | 1 |
| Weinberger, M | 1 |
| Zimhony, O | 1 |
| Chowers, M | 1 |
| Weber, G | 1 |
| Potasman, I | 1 |
| Chazan, B | 1 |
| Kassis, I | 1 |
| Shalit, I | 1 |
| Block, C | 1 |
| Keller, N | 1 |
| Kontoyiannis, DP | 1 |
| Giladi, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Adjunctive Sertraline for the Treatment of HIV-Associated Cryptococcal Meningitis[NCT01802385] | Phase 3 | 460 participants (Actual) | Interventional | 2015-03-09 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Center for Epidemiologic Studies in Depression (CES-D) scale at 14 weeks. CES-D scores are based on a 20 item survey with total scores ranging from 0 to 60. Higher scores suggest a greater presence of depressive symptoms. A CES-D score of 16 or higher is interpreted to indicate a risk for depression. (NCT01802385)
Timeframe: 14 weeks
| Intervention | score on a scale (Mean) |
|---|---|
| Placebo | 16.6 |
| Sertraline 400mg | 13.2 |
Number of participants with sterile cerebrospinal fluid at 2 weeks (NCT01802385)
Timeframe: 14 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo | 90 |
| Sertraline 400mg | 101 |
Event free survival of composite events of: death,central nervous system (CNS) cryptococcal-related paradoxical immune reconstitution inflammatory syndrome (IRIS) or culture-positive relapse. (NCT01802385)
Timeframe: 18 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo | 116 |
| Sertraline 400mg | 103 |
Cumulative incidence of central nervous system (CNS) cryptococcal-related paradoxical immune reconstitution inflammatory syndrome (IRIS) or culture-positive relapse (NCT01802385)
Timeframe: 18 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo | 9 |
| Sertraline 400mg | 5 |
Quantitative neurocognitive performance Z-score (QNPZ-8) at 14 weeks. The QNPZ-8 is a mean score of testing of 8 neurocognitive domains. Eqach domain is scaled based on a Z-score where the mean = 0 for the HIV-negative Ugandan population, accounting for age and educational status. Each +1 unit is one standard deviation better than the population norm. Each -1 unit is one standard deviation worse than the population norm. (NCT01802385)
Timeframe: 14 weeks
| Intervention | score (Mean) |
|---|---|
| Placebo | -1.4 |
| Sertraline 400mg | -1.3 |
Safety and tolerability of adjunctive sertraline (grade 4-5) adverse reactions (NCT01802385)
Timeframe: 18 weeks
| Intervention | events (Number) |
|---|---|
| Placebo | 121 |
| Sertraline 400mg | 141 |
18-week survival. The comparison will be between sertraline 400mg group and placebo (NCT01802385)
Timeframe: 18 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo | 125 |
| Sertraline 400mg | 109 |
To determine whether adjunctive sertraline will lead to a faster rate of fungal clearance from cerebrospinal fluid (CSF), as measured by early fungicidal activity (EFA) of clearance of the Cryptococcus colony forming units (cfu) per mL of CSF per day, compared to standard therapy alone. (NCT01802385)
Timeframe: 14 days
| Intervention | -log10 CFU/ml/day (Mean) | |
|---|---|---|
| General Linear Regression | Mixed-Effects Regression | |
| Placebo | 0.47 | 0.33 |
| Sertraline 400mg | .43 | .33 |
4 reviews available for fluconazole and Co-infection
| Article | Year |
|---|---|
Antifungal therapy in the management of fungal secondary infections in COVID-19 patients: A systematic review and meta-analysis.
Topics: Antifungal Agents; Coinfection; COVID-19; Fluconazole; Humans; Mycoses; Prospective Studies; Retrosp | 2022 |
Prosthetic joint infection due to Candida species: Case series and review of literature.
Topics: Aged; Aged, 80 and over; Antifungal Agents; Bacterial Infections; Candida albicans; Coinfection; Com | 2020 |
Leave no one behind: response to new evidence and guidelines for the management of cryptococcal meningitis in low-income and middle-income countries.
Topics: Africa; Amphotericin B; Antifungal Agents; Coinfection; Cryptococcus neoformans; Developing Countrie | 2019 |
Comparison of flucytosine and fluconazole combined with amphotericin B for the treatment of HIV-associated cryptococcal meningitis: a systematic review and meta-analysis.
Topics: Amphotericin B; Antifungal Agents; Coinfection; Drug Therapy, Combination; Fluconazole; Flucytosine; | 2014 |
3 trials available for fluconazole and Co-infection
| Article | Year |
|---|---|
Effects of fluconazole on the clinical outcome and immune response in fungal co-infected tuberculosis patients.
Topics: Aged; Aged, 80 and over; Body Mass Index; Chemokine CXCL10; Chemokine CXCL11; Chemokine CXCL9; Chemo | 2018 |
AMBITION-cm: intermittent high dose AmBisome on a high dose fluconazole backbone for cryptococcal meningitis induction therapy in sub-Saharan Africa: study protocol for a randomized controlled trial.
Topics: AIDS-Related Opportunistic Infections; Amphotericin B; Antifungal Agents; Botswana; Clinical Protoco | 2015 |
Increased Antifungal Drug Resistance in Clinical Isolates of Cryptococcus neoformans in Uganda.
Topics: Amphotericin B; Antifungal Agents; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Coinfection; Cr | 2015 |
20 other studies available for fluconazole and Co-infection
| Article | Year |
|---|---|
Pseudomonas Synergizes with Fluconazole against
Topics: Animals; Antifungal Agents; Candida; Candida albicans; Coinfection; Drug Resistance, Fungal; Flucona | 2022 |
Competition for Iron during Polymicrobial Infections May Increase Antifungal Drug Susceptibility-How Will It Impact Treatment Options?
Topics: Antifungal Agents; Candida albicans; Candidiasis; Coinfection; Drug Resistance, Fungal; Fluconazole; | 2022 |
Synergistic Effects of Fluconazole Combined with Doxycycline Against Dual-Species Cultures of
Topics: Anti-Bacterial Agents; Antifungal Agents; Biofilms; Candida albicans; Coinfection; Doxycycline; Drug | 2022 |
Assessment of Risk Factors and Clinical Outcomes in Hospitalized COVID-19 Patients with Candida spp. Co-infections: Species Distribution and Antifungal Susceptibility Patterns of Isolates.
Topics: Antifungal Agents; Candida; Candida albicans; Candidiasis; Coinfection; COVID-19; Drug Resistance, F | 2023 |
Assessment of Risk Factors and Clinical Outcomes in Hospitalized COVID-19 Patients with Candida spp. Co-infections: Species Distribution and Antifungal Susceptibility Patterns of Isolates.
Topics: Antifungal Agents; Candida; Candida albicans; Candidiasis; Coinfection; COVID-19; Drug Resistance, F | 2023 |
Assessment of Risk Factors and Clinical Outcomes in Hospitalized COVID-19 Patients with Candida spp. Co-infections: Species Distribution and Antifungal Susceptibility Patterns of Isolates.
Topics: Antifungal Agents; Candida; Candida albicans; Candidiasis; Coinfection; COVID-19; Drug Resistance, F | 2023 |
Assessment of Risk Factors and Clinical Outcomes in Hospitalized COVID-19 Patients with Candida spp. Co-infections: Species Distribution and Antifungal Susceptibility Patterns of Isolates.
Topics: Antifungal Agents; Candida; Candida albicans; Candidiasis; Coinfection; COVID-19; Drug Resistance, F | 2023 |
Cryptococcus genetic diversity and mixed infections in Ivorian HIV patients: A follow up study.
Topics: Adult; Amphotericin B; Antifungal Agents; Coinfection; Cryptococcosis; Cryptococcus; Cryptococcus ne | 2019 |
Triple infection with Cryptococcus, varicella-zoster virus, and Mycobacterium abscessus in a patient with anti-interferon-gamma autoantibodies: a case report.
Topics: Acyclovir; Amphotericin B; Autoantibodies; Coinfection; Cryptococcosis; Fluconazole; Herpesvirus 3, | 2020 |
A rare case of Trichosporon mycotoxinivorans and Cryptococcus neoformans co-infection in lung.
Topics: Aged; Antifungal Agents; Biopsy; Bronchoalveolar Lavage Fluid; Coinfection; Cryptococcosis; Cryptoco | 2020 |
Candida duobushaemulonii sepsis and Candida auris co-isolation following hospitalisation in Vietnam.
Topics: Aged, 80 and over; Amphotericin B; Antifungal Agents; Candida; Candidemia; Candidiasis, Cutaneous; C | 2020 |
Dynamics of Mixed- Candida Species Biofilms in Response to Antifungals.
Topics: Amphotericin B; Antifungal Agents; Biofilms; Candida; Candida glabrata; Candida tropicalis; Candidia | 2018 |
Mixed yeast infections in Taiwan.
Topics: Antifungal Agents; Candida; Candidiasis; Coinfection; Drug Resistance, Fungal; Epidemiological Monit | 2018 |
Cryptococcoma of a transplanted kidney in a patient presenting with recurrent urinary tract infection: a case report.
Topics: Adult; Antifungal Agents; Bacterial Infections; Biopsy; Coinfection; Cryptococcosis; Cryptococcus ne | 2018 |
Nodulo-ulcerative and erythrodermic secondary syphilis in human immunodeficiency virus-infected individuals.
Topics: Administration, Oral; Adult; AIDS-Related Opportunistic Infections; Anti-Infective Agents; Chancre; | 2019 |
Successful Treatment of Cutaneous Blastomycosis in a Renal Transplant Patient With BK Virus Infection: A Case Report.
Topics: Amphotericin B; Antifungal Agents; BK Virus; Blastomycosis; Coinfection; Fluconazole; Humans; Immuno | 2019 |
Endocarditis due to a co-infection of Candida albicans and Candida tropicalis in a drug abuser.
Topics: Adult; Amphotericin B; Antifungal Agents; Candida albicans; Candida tropicalis; Candidiasis; Coinfec | 2013 |
Frequency of clinically isolated strains of oral Candida species at Kagoshima University Hospital, Japan, and their susceptibility to antifungal drugs in 2006-2007 and 2012-2013.
Topics: Adult; Aged; Aged, 80 and over; Amphotericin B; Antifungal Agents; Autoimmune Diseases; Bacterial Lo | 2014 |
In vitro interactions between fluconazole and minocycline against mixed cultures of Candida albicans and Staphylococcus aureus.
Topics: Anti-Bacterial Agents; Antifungal Agents; Biofilms; Calcium; Candida albicans; Candidiasis; Coinfect | 2015 |
Clinical implications of oral candidiasis: host tissue damage and disseminated bacterial disease.
Topics: Animals; Candida albicans; Candidiasis, Oral; Coinfection; Disease Models, Animal; Female; Fluconazo | 2015 |
Positive peritoneal fluid fungal cultures in postoperative peritonitis after bariatric surgery.
Topics: Adult; Ascitic Fluid; Bacteria; Bariatric Surgery; Candida; Candidiasis; Coinfection; Drug Resistanc | 2015 |
Candida glabrata Binding to Candida albicans Hyphae Enables Its Development in Oropharyngeal Candidiasis.
Topics: Animals; Candida albicans; Candida glabrata; Candidiasis, Oral; Cell Wall; Coinfection; Female; Fluc | 2016 |
Antibiotic exposure as a risk factor for fluconazole-resistant Candida bloodstream infection.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Antifungal Agents; Bacteria; Bacterial Infect | 2012 |